Impact Biomedical Inc. Announces 1-for-12.62 Reverse Stock Split

Impact Biomedical Inc. (NYSE American: IBO) announced that its Board of Directors approved a 1-for-12.62 reverse stock split of its common stock, effective September 23, 2026. This action is intended to support the company's proposed business combination with Zoar Limited and its continued listing objectives on the NYSE American Exchange.